Ben-Gurion University of the Negev

Wave Energy Developer, Eco Wave Power, Strengthens Management - Appoints Chief Operating Officer

Retrieved on: 
Wednesday, October 13, 2021

STOCKHOLM, Oct. 13, 2021 /PRNewswire/ -- Publicly traded wave energy developer, Eco Wave Power Global AB (publ) ("Eco Wave Power") (Nasdaq US: WAVE, Nasdaq First North: ECOWVE), announces today the appointment of Mr. Avi Waller as Chief Operating Officer for the Eco Wave Power Group.

Key Points: 
  • STOCKHOLM, Oct. 13, 2021 /PRNewswire/ -- Publicly traded wave energy developer, Eco Wave Power Global AB (publ) ("Eco Wave Power") (Nasdaq US: WAVE, Nasdaq First North: ECOWVE), announces today the appointment of Mr. Avi Waller as Chief Operating Officer for the Eco Wave Power Group.
  • Mr. Waller will begin his employment immediately and will be based in Eco Wave Power's headquarters in Tel Aviv, Israel.
  • "I'm truly excited to see Avi join Eco Wave Power as our COO.
  • Eco Wave Power Global ("Eco Wave Power") is a leading onshore wave energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity.

Tachyum Hires Pini Herman as Senior Director of Solutions Engineering

Retrieved on: 
Tuesday, October 12, 2021

Tachyum today announced the appointment of Pini Herman as its new Senior Director of Solutions Engineering.

Key Points: 
  • Tachyum today announced the appointment of Pini Herman as its new Senior Director of Solutions Engineering.
  • He comes to Tachyum from Cadence Design Systems, where he served as Hardware Engineering Architect.
  • Having worked with Pini at Skyera, I know that we found the right person to help lead solutions engineering efforts as we ready Prodigy for volume production, said Dr. Radoslav Danilak, founder and CEO of Tachyum.
  • I am so happy to rejoin the talented Tachyum team and to play a part in its success, said Pini Herman.

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction

Retrieved on: 
Thursday, September 30, 2021

BURLINGTON, Mass. and JERUSALEM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay'' or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced data published in World Psychiatry, the official publication of the World Psychiatric Association, from a pivotal, multicenter, placebo-controlled, double-blind clinical trial, supporting the use of Deep TMS™ as a safe and effective treatment for tobacco use disorder – one of the most common substance use disorders and leading cause of preventable death worldwide.

Key Points: 
  • With 15 sites enrolled in the CMR, BrainsWay has also transitioned to the limited rollout of systems to existing customers to support growing demand.
  • There is still much work to be done to explore the full utility of Deep TMS in the field of addiction.
  • The global economic burden of smoking is estimated to be $1.852 trillion every year: nearly 2% of the World GDP.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

Inspira Technologies Announces First Half 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 13, 2021

Ltd (Nasdaq: IINN) (Nasdaq: IINNW)(the "Company" or "Inspira"), a specialty medical device company engaged in the research, development, manufacturing and marketing of proprietary respiratory support technologies, announced today its financial results as of and for the six months endedJune 30, 2021.

Key Points: 
  • Ltd (Nasdaq: IINN) (Nasdaq: IINNW)(the "Company" or "Inspira"), a specialty medical device company engaged in the research, development, manufacturing and marketing of proprietary respiratory support technologies, announced today its financial results as of and for the six months endedJune 30, 2021.
  • We plan to target the 20 million patients admitted to Intensive Care Units (ICUs) each year who are being placed on mechanical ventilation.
  • We have developed a "razor, razorblade" business model, under which we expect disposable sales to grow with the futuremass deployment of our ART system," Mr. Ben-Noon added.
  • Financial Results for the Six Months EndedJune 30, 2021
    Cash, cash equivalents, and short-term bank deposits were $4,355,000 as ofJune 30, 2021, compared to $496,000 as of December 31, 2020.

HPC-AI Advisory Council Invites Participation in Ninth Annual Advanced RDMA Programming Workshop and Competition

Retrieved on: 
Wednesday, August 11, 2021

Promoter of high performance computing (HPC) and artificial intelligence (AI) education and expertise, the HPC-AI Advisory Council (HPCAIAC) today announced the registration opening for its 9th Annual Advanced RDMA Programming Workshop and Competition (22-29 August).

Key Points: 
  • Promoter of high performance computing (HPC) and artificial intelligence (AI) education and expertise, the HPC-AI Advisory Council (HPCAIAC) today announced the registration opening for its 9th Annual Advanced RDMA Programming Workshop and Competition (22-29 August).
  • Combining an immersive 4.5-day workshop followed with the 3-day challenge, participants will be introduced to advanced technologies, programming and optimization in server-storage communication efficiencies.
  • The four and a half day workshop will feature leading global experts, lectures, demonstrations, and hands-on training in advanced Remote Direct Memory Access (RDMA) programming.
  • In addition to the introduction of advanced RDMA programming, expert instructors contributing to the HPCAIACs annual training and development workshop will provide in-depth training on optimizing performance for a variety of network offload features.

Ben-Gurion University Researchers to Develop Novel Biological Treatment for Inflammatory Bowel Diseases

Retrieved on: 
Wednesday, August 11, 2021

BEER-SHEVA, Israel, Aug. 11, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases (IBD) by sequestering inflammation-inducing molecules secreted by gut bacteria.

Key Points: 
  • BEER-SHEVA, Israel, Aug. 11, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases (IBD) by sequestering inflammation-inducing molecules secreted by gut bacteria.
  • Several recent studies show that succinate acts as a pro-inflammatory metabolite, in particular driving inflammatory activity of macrophages.
  • "Current treatments for IBD include antibiotics, steroids and biological treatments aimed at inhibiting the activity of the immune system.
  • BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students.

ScoutCam Appoints Professor Jacob Bortman, Brigadier General (Ret.) Head of Material Directorate of the Israeli Air Force as Director of Business Development Industry 4.0

Retrieved on: 
Thursday, February 18, 2021

Prof. Bortman brings to ScoutCam an accomplished military background where he reached the rank of Brigadier General (Ret.)

Key Points: 
  • Prof. Bortman brings to ScoutCam an accomplished military background where he reached the rank of Brigadier General (Ret.)
  • in the Israeli Air Force (IAF).
  • Following his retirement from the IAF, Prof. Bortman transitioned to academia where he now teaches and researches as a professor of mechanical engineering at Ben-Gurion University in Israel.
  • We are excited to join forces with Prof. Bortman and to tap into his unique expertise said Dr. Yaron Silberman, Chief Executive Officer of ScoutCam.

Ben-Gurion University Researchers Introduce New Method for Diagnosing Neurological and Psychiatric Conditions

Retrieved on: 
Tuesday, February 9, 2021

BEER-SHEVA, Israel, Feb. 9, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) have developed a new method for rapidly diagnosing brain blood vessel pathology that may lead to neurodegenerative diseases, such as Alzheimer's disease, as well as other neurological and psychiatric conditions, including epilepsy, traumatic brain injury and stroke.

Key Points: 
  • BEER-SHEVA, Israel, Feb. 9, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) have developed a new method for rapidly diagnosing brain blood vessel pathology that may lead to neurodegenerative diseases, such as Alzheimer's disease, as well as other neurological and psychiatric conditions, including epilepsy, traumatic brain injury and stroke.
  • The novel diagnostic method is based on findings from the lab of Prof. Friedman that patients with Alzheimer's disease and other brain conditions display nonconvulsive epileptic seizure-like activity that can be detected by EEG recordings.
  • "This new approach for diagnosing neurological conditions based on analysis of changes of blood vessels in the brain can be valuable for the early detection of Alzheimer's disease and other neurological conditions, at the stage when treatment can still slow down disease progression.
  • BGN Technologiesis the technology transfer companyof Ben-Gurion University, the third largest university in Israel.

Ben-Gurion University Researchers Develop Machine Learning Platform to Streamline Clinical Trials

Retrieved on: 
Wednesday, October 21, 2020

BEER-SHEVA, Israel, Oct. 21, 2020 /PRNewswire/ --Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel platform to streamline clinical trials, lower costs, and increase the efficiency and success rate of the drug or medical device development process.

Key Points: 
  • BEER-SHEVA, Israel, Oct. 21, 2020 /PRNewswire/ --Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel platform to streamline clinical trials, lower costs, and increase the efficiency and success rate of the drug or medical device development process.
  • The new platform leverages machine learning to optimize a clinical trial's chances of success, analyzing patient population recruitment and dropout rate, as well as identifying and prioritizing monitored markers.
  • "Clinical trials haven't fundamentally changed in the past two decades," said Prof. Lerner.
  • BGN Technologiesis the technology transfer companyof Ben-Gurion University, the third largest university in Israel.

LIGC announces $3M USD Series A funding from Hubei Forbon Technology Co. Ltd

Retrieved on: 
Tuesday, September 15, 2020

TEL AVIV, Israel, Sept. 15, 2020 /PRNewswire-PRWeb/ -- Today, Israeli startup LIGC announced a $3M USD Series A round from public listed Wuhan-based Hubei Forbon Technology Co. Ltd (300387.SZ).

Key Points: 
  • TEL AVIV, Israel, Sept. 15, 2020 /PRNewswire-PRWeb/ -- Today, Israeli startup LIGC announced a $3M USD Series A round from public listed Wuhan-based Hubei Forbon Technology Co. Ltd (300387.SZ).
  • The funding will be used to scale and manufacture LIGC's Laser-Induced Graphene filters (LIG).
  • The technology was developed by Houston's Rice University in partnership with Ben-Gurion University (BGU) of the Negev in Israel and was licensed from BGN technologies, the technology transfer company of BGU.
  • In addition, LIGC active filters require lower maintenance than other filters and are safe to the operator during maintenance and replacement.